1-(3-bromo-propyl)-1,2,3,4-tetrahydro-quinoline | 34579-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(3-bromo-propyl)-1,2,3,4-tetrahydro-quinoline
• 英文别名: 1-(3-Brom-propyl)-1,2,3,4-tetrahydro-chinolin；3-(1,2,3,4-tetrahydroquinolin-1-yl)propyl bromide；N-(3-Brompropyl)-tetrahydrochinolin；1-(3-bromopropyl)-3,4-dihydro-2H-quinoline
• CAS: 34579-45-8
• 化学式: C₁₂H₁₆BrN
• 分子量: 254.17
• InChiKey: KADJPMRDABMGQM-UHFFFAOYSA-N

物化性质

• 沸点：
  346.4±25.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-bromo-propyl)-1,2,3,4-tetrahydro-quinoline 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Kaufmann; Vonderwahl, Chemische Berichte, 1912, vol. 45, p. 1406

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 、 1,3-二溴丙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以53.47 %的产率得到1-(3-bromo-propyl)-1,2,3,4-tetrahydro-quinoline
  参考文献：
  名称：

  发现基于乙内酰硫脲的雄激素受体拮抗剂，可有效降解，用于治疗前列腺癌

  摘要：

  前列腺癌（PC）是全世界男性中最常见的癌症之一，雄激素受体（AR）是治疗 PC 的经过充分验证的药物靶点。然而，随着时间的推移，PC 通常会对 AR 拮抗剂表现出耐药性。因此，迫切需要寻找新型有效的 PC 治疗药物。设计、合成和评估了一系列新型基于乙内酰硫脲的 AR 拮抗剂，这些拮抗剂能够有效降解 AR。基于我们之前的SAR和进一步的结构优化，发现了一种具有双重机制的工具分子，包括提高拮抗活性和有效降解（AR-fl和AR-V7）。而且，还可以有效阻断AR核转位并抑制AR/AR-V7异二聚化，从而抑制下游基因转录。重要的是，在 LNCaP（TGI：70.70%）和 22Rv1（TGI：78.89%）异种移植模型中显示出强大的功效。这为治疗前列腺癌提供了新的设计策略和有利的潜在化合物。

  DOI：

  10.1016/j.ejmech.2023.115490

文献信息

• Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
  申请人：Debnath Bhunia

  公开号：US20070093476A1

  公开（公告）日：2007-04-26

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（CH2）pB（CH2）q′（CH2）rB（CH2）pD（CH2）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。
• [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040102A3

  公开（公告）日：2006-03-23
• NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1680397A2

  公开（公告）日：2006-07-19
• [EN] NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005040102A2

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p’ (CH2)pB(CH2)q’ (CH2)rB(CH2)pD(CH2)q’ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, -S(O)2-R8 or -C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.
• Kaufmann; Vonderwahl, Chemische Berichte, 1912, vol. 45, p. 1406
  作者：Kaufmann、Vonderwahl

  DOI：——

  日期：——